Physician profile
Mark S Codella
NPI 1356361919
$9,814.76
in general payments reported to CMS, 2019-2025
36 companies · $1,738 in 2025
The $1,738 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $715 · 2021: $1,062 · 2022: $1,533 · 2023: $1,816 · 2024: $2,009 · 2025: $1,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,517 · Education: $46.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,517.14 |
| Education | $46.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,224.33 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,380.07 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Gilead Sciences, INC. | $1,048.22 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $666.47 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $479.16 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Celgene Corporation | $442.36 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $387.21 | 2019-2025 | Sucraid |
| Redhill Biopharma INC. | $338.74 | 2020-2022 | |
| Pfizer INC. | $277.46 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $267.69 | 2020-2023 | |
| Genzyme Corporation | $261.74 | 2022-2025 | |
| Ardelyx, INC. | $249.58 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $225.64 | 2020-2023 | Linzess |
| Intercept Pharmaceuticals, INC. | $210.28 | 2019-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $203.70 | 2024-2025 | Iqirvo, Bylvay |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $187.79 | 2023-2025 | Omvoh |
| Ucb, INC. | $177.12 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $115.27 | 2019-2023 | Dificid |
| Celltrion USA INC. | $89.26 | 2024-2025 | Vegzelma, Zymfentra |
| Shionogi INC | $86.68 | 2019 | |
| Madrigal Pharmaceuticals | $67.42 | 2025 | Rezdiffra |
| Evoke Pharma, INC. | $62.05 | 2023-2025 | Gimoti |
| Allergan, INC. | $49.57 | 2019-2020 | |
| Braintree Laboratories, INC. | $48.31 | 2020-2023 | Sutab |
| Alfasigma USA, INC. | $42.91 | 2020 | |
| Aimmune Therapeutics, INC. | $30.36 | 2023-2024 | |
| Laborie Medical Technologies Corp. | $30.06 | 2023 | |
| Ferring Pharmaceuticals INC. | $28.72 | 2020-2021 | |
| Erbe USA INC | $27.00 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $19.55 | 2021 | |
| Exact Sciences Corporation | $19.04 | 2023 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $18.25 | 2023 | Dupixent |
| Olympus America INC. | $14.62 | 2021 | |
| Fresenius Kabi USA, LLC | $13.75 | 2024 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $13.50 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Codella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.